StockNews.com downgraded shares of Immunic (NASDAQ:IMUX - Free Report) from a hold rating to a sell rating in a report published on Thursday.
IMUX has been the topic of several other research reports. D. Boral Capital restated a "buy" rating and issued a $17.00 price objective on shares of Immunic in a research note on Wednesday, February 26th. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Immunic in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Immunic presently has an average rating of "Buy" and a consensus target price of $12.67.
Get Our Latest Research Report on Immunic
Immunic Trading Up 0.9 %
NASDAQ:IMUX traded up $0.01 during mid-day trading on Thursday, hitting $1.15. 264,060 shares of the company's stock traded hands, compared to its average volume of 595,058. The firm has a market capitalization of $103.59 million, a price-to-earnings ratio of -0.93 and a beta of 1.89. The firm has a 50 day moving average of $1.06 and a two-hundred day moving average of $1.22. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11.
Institutional Investors Weigh In On Immunic
Several institutional investors and hedge funds have recently bought and sold shares of IMUX. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock valued at $169,000 after acquiring an additional 42,383 shares in the last quarter. State Street Corp lifted its stake in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company's stock worth $276,000 after purchasing an additional 11,642 shares during the period. Jane Street Group LLC boosted its holdings in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock valued at $116,000 after purchasing an additional 38,553 shares in the last quarter. Virtu Financial LLC acquired a new stake in Immunic during the third quarter valued at approximately $50,000. Finally, HB Wealth Management LLC bought a new stake in shares of Immunic in the 4th quarter valued at approximately $81,000. Institutional investors own 51.82% of the company's stock.
About Immunic
(
Get Free Report)
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Further Reading
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
